Preclinical comparison of three indenoisoquinolone candidates in tumor-bearing dogs:
A pilot study of topotecan in dogs with lymphoma

This clinical trial sponsored by the National Cancer Institute (NCI) assesses the safety and effectiveness of Topotecan and novel Topoisomerase I inhibitors when given to dogs with lymphoma.

Eligibility Criteria

- Histologically confirmed LSA
- Minimal node size of 2 cm
- Both newly diagnoses and those with recurrent/relapse disease
- Favorable performance status: Grade 0 or 1
- No concurrent chemotherapy or radiation therapy
- Corticosteroid washout of 7 days prior to study drug
- No significant morbid illness

Clinician: Dr. Bill Kisseberth

Maintenance Therapy with Toceranib (Palladia) Following Doxorubicin-Based Chemotherapy for Canine Splenic Hemangiosarcoma

Hemangiosarcoma's have a very aggressive biologic behavior, and in most cases, rapid and widespread metastasis. The hypothesis to be investigated is that dogs with splenic HSA treated with adjuvant doxorubicin (DOX)-based chemotherapy followed by Palladia will have prolonged disease-free and overall survival times, when compared to a historical group of dogs treated with DOX-based chemotherapy alone. To test this, we are performing an open-label multicenter clinical trial, in dogs with splenic HSA treated with DOX followed by Palladia.

Eligibility Criteria

- Histologically confirmed, stage I or II (i.e., no evidence of metastasis at time of diagnosis) splenic HSA
- Undergone splenectomy <14 days prior to treatment initiation
- Received 5 doses of single-agent doxorubicin (every 2 weeks) following spleen removal

Clinician: Dr. Cheryl London
Safety Evaluation of Combination Vinblastine and Toceranib (Palladia®): A Phase Dose Finding Study

Mast cell tumors (MCTs) are the second most common cancer in dogs. Vinblastine chemotherapy is the current standard of care for the treatment of high-risk or unresectable MCTs in dogs. The purpose of this clinical trial is to determine the maximally tolerated dose of Palladia when used in combination with a standard dose of vinblastine in dogs with MCTs.

Eligibility Criteria:
- Confirmed non-resectable MCT’s or the owners choose not to undergo surgical removal of the tumor

Clinician: Dr. Cheryl London

Palladia Plus Radiation Therapy for Canine Mast Cell Tumor

This is a multicenter phase-2 clinical trial determining the tolerability and adverse effect profile of combined treatment with Palladia and hypofractionated radiation therapy in dogs with MCT in addition to the objective response rate and progression-free interval in dogs with measurable MCT.

Eligibility Criteria:
- Histologically confirmed cutaneous/subcutaneous MCT, with or without regional LN involvement, where surgical excision is not feasible or had been declined

Clinician: Dr. Cheryl London

Evaluation of Orally Administered mTOR inhibitor Rapamycin in Tumor Bearing Dogs

This clinical trial sponsored by the National Cancer Institute (NCI) is an open label, prospective preclinical trial of orally administered rapamycin in tumor bearing dogs.

*Enrollment Open in April*

Eligibility Criteria:
- Histologically confirmed malignancy
- Measurable disease
- Both newly diagnosed and those with recurrent disease
- < 15 kg in size
- No concurrent chemotherapy or radiation therapy
- 72 hour NSAID washout prior to study initiation
- No history of IBD or chronic gastroenteritis; no significant co-morbid illness

Clinician: Dr. Bill Kisseberth
Dermatology
• Primary Secretory Otitis Media in Cavalier King Charles Spaniels

Equine
• Cell-Mediated Bone Morphogenetic Protein Gene Therapy for Bone Healing in Horses

Internal Medicine
• A Study to Evaluate the Efficacy and Safety of an Alternative Antibiotic Treatment Regimen for Lower Urinary Tract Infection in Dogs

Oncology
• Liposomal Clodronate for the Treatment of Malignant Histiocytosis
• Dietary Nucleotides in Dogs Undergoing Anticancer Chemotherapy for LSA or OSA

Radiology
• Computed Tomography (CT) Imaging in Canine Osteosarcoma of the Appendicular Skeleton

Surgery
• Evaluation of Novel Spinal and Orthopedic Devices in Dogs

Critical Care
• Characterization of Coagulation Changes in Acutely Traumatized Dogs using Thromboelastography
• Abdominal Effusion Associated with Decompressive Cystocentesis in Male Cats with Urethral Obstruction
• Incidence of Urinary Tract Infection Associated with Urinary Catheterization in Feline Urethral Obstruction

Food Animal
• The Effects of Mycoplasma Haemolamae Genetics to Virulence, Detection, and Vertical Transmission

Equine
• Bacterial Translocation in Horses with Strangulating Small Intestinal Lesions

Shelter Medicine
• Effect of Cage Enrichment and Predictability on Health Outcomes in Shelter Cats

*Recruiting Clinical Trials*

Completed Studies

Cardiology
• Prevalence of Systemic Arterial Hypertension and Proteinuria in Shetland Sheepdogs

Oncology
• Study to Determine Efficacy and Safety of Paclical Vet (paclitaxel) vs CeeNu in MCT
• Efficacy Evaluation of Implanted Agarose-Agarose Macrobeads Containing Mouse Renal Adenocarcinoma Cells in Dogs with Spontaneous Hemangiosarcoma (HSA).

Clinical Trials Office
0117 Veterinary Medical Center
601 Vernon L. Tharp Street
Columbus, OH 43210

Phone (614) 292-9554
Phone (614) 688-5713
Fax (614) 292-6464